Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer

Investigational New Drugs

Volumn 20, Issue 2, 2002, Pages 145-158

  Gleave, Martin E ^a   Zellweger, Toby ^a   Chi, Kim ^a   Miyake, Hideaki ^a   Kiyama, Satoshi ^a   July, Laura ^a   Leung, Simon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense oligonucleotide; Apoptosis; Bcl 2; Clusterin; IGF 1; IGFBP; Prostate cancer; Taxol; TRPM 2

Indexed keywords

ANDROGEN; ANTISENSE OLIGONUCLEOTIDE; CLUSTERIN; PROTEIN BCL 2; PROTEIN BCL XL; SOMATOMEDIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CASTRATION; CELL SURVIVAL; CHEMOSENSITIVITY; GENE EXPRESSION; GENE TARGETING; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CLUSTERIN; GENES, BCL-2; GLYCOPROTEINS; HUMANS; MALE; MOLECULAR CHAPERONES; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; THIONUCLEOTIDES; UP-REGULATION;

EID: 0036285604     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015694802521     Document Type: Review

References (85)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. Management of hormone refractory prostate cancer: Current standards and future prospects
3. Phase II trial of 96-hour paclitaxel plus oral estra-mustine phosphate in metastatic hormone-refractory prostate cancer
4. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
5. Phase II trial of oral estramustine, oral etopside, and intravenous paclitaxel in hormone-refractory prostate cancer
6. Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer
7. Antisense Bcl-2 oligodeo-xynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
8. Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models
9. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
10. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway
11. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the human prostate cancer cell Line LNCaP
12. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
13. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
14. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
15. Animal models in prostate cancer
16. The LNCaP cell line - A new model for studies on human prostatic carcinoma
17. Serum PSA levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors
18. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing pro-static carcinoma xenograft: LuCaP 23
19. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
20. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins
21. Antisense Bcl-xL and Bcl-2 Oligodeoxynucleotides synergistically enhance taxol chemo-sensitivity and delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
22. Progression to androgen-independence is delayed by antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
23. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue arrays
24. Therapeutic applications of oligonucleotides
25. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice
26. Anti-tumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
27. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
28. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
29. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression
30. Interactions among members of the bcl-2 protein family analysed with a yeast two-hybrid systems
31. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
32. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers
33. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
34. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy
35. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL
36. Antisense Bcl-2 Oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
37. Use of anti-sense oligonucleotides to target anti-apoptotic genes to enhance androgen- and chemo-sensitivity and delay androgen-independent progression in prostate cancer
38. Bcl2 is the guardian of micro-tubule integrity
39. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligonucleotide and paclitaxel in the LNCaP tumour model
40. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
41. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
42. A phase I/ia clinical trial of antiscnsc Bcl-2 oligodeoxynucleotides plus mitoxanthrone in men with hormone refractory prostate cancer
43. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer
44. Direct trans-activation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB
45. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation
46. Overexpression of clusterin in human breast carcinoma
47. Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas
48. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas
49. Apolipoprotein J (clusterin) and Alzheimer's disease
50. Clusterin and the kidney
51. Androgen-repressed messages in the rat ventral prostate
52. Programmed cell death during regression of PC- 82 human prostate cancer following androgen ablation
53. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy
54. Clusterin. Physiologic and pathophysiologic considerations
55. Active cell death in hormone-dependent tissues
56. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death
57. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis
58. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat
59. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties
60. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus
61. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death
62. Clusterin: A role in cell survival in the face of apoptosis?
63. Clusterin is a secreted mammalian chaperone
64. Stress-induced transcription of the clusterin/apoJ gene
65. Clusterin has chaperone-like activity similar to that of small heat shock proteins
66. Prevention of cell death induced by tumor necrosis factor in a LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin)
67. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2 (TRPM-2), in prostate cancer xenograft models
68. Antisense TRPM-2 Oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
69. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin
70. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
71. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
72. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
73. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
74. Activation of the human androgen receptor through a protein kinase A signaling pathway
75. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
76. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
77. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
78. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway
79. Insulin-like growth factors and their binding proteins: Biological actions
80. The IGF axis in the prostate
81. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis
82. Antisense insulin-like growth factor binding protein-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the human LNCaP tumor model via negative modulation of insulin-like growth factor-I action
83. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5
84. Biologic effects of PSA as an IGFBP- 3 protease
85. Antisense insulin-like growth factor binding protein-5 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model via negative modulation of insulin-like growth factor-I action